Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency

09/24/2021 | 04:24pm EDT

Pfizer Inc. and OPKO Health Inc. announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for somatrogon, a once-weekly long-acting recombinant human growth hormone, for the treatment of growth hormone deficiency (GHD) in pediatric patients. The Prescription Drug User Fee Act (PDUFA) goal date has been extended by three months to January 2022, as a result of Pfizer’s submission of additional data to the original BLA. In 2014, Pfizer and OPKO entered into a worldwide agreement for the development and commercialization of somatrogon for the treatment of GHD. Under the agreement, OPKO is responsible for conducting the clinical program and Pfizer is responsible for registering and commercializing the product for GHD.


ę S&P Capital IQ 2021
All news about PFIZER, INC.
10/25MODERNA : U.S. administers 414.3 mln doses of COVID-19 vaccines - CDC
RE
10/25PFIZER : Moderna says studies show COVID-19 vaccine safe, effective in children 6-11
AQ
10/25PFIZER : Moderna says its low-dose COVID shot works for kids 6 to 11
AQ
10/25Moderna Shares Higher After Interim Data for Covid-19 Vaccine in Children
DJ
10/25Pfizer, Moderna and J&J Booster Shots Now Available at Walmart and Sam's Club Pharmacie..
AQ
10/25ANALYSIS : Capitol Hill drug pricing reform opponents among the biggest beneficiaries of p..
RE
10/25UNIVERSITY OF BIRMINGHAM : A third of leukaemia patients do not generate any antibody resp..
AQ
10/25FORMER EMPLOYEE : Pfizer is like an 'abusive, rich husband' with frequent virtue signallin..
AQ
10/25PFIZER : Prime Minister issues vaccine call to arms ahead of winter
AQ
10/25PFIZER : United States Donates 1.4 Million More COVID-19 Pfizer Vaccines to Egypt
AQ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 557 M - -
Net income 2021 18 627 M - -
Net Debt 2021 29 307 M - -
P/E ratio 2021 12,7x
Yield 2021 3,66%
Capitalization 242 B 242 B -
EV / Sales 2021 3,33x
EV / Sales 2022 3,79x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 43,15 $
Average target price 45,72 $
Spread / Average Target 5,96%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.17.25%241 929
JOHNSON & JOHNSON4.26%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
ELI LILLY AND COMPANY45.14%220 979
MERCK & CO., INC.-0.79%205 421